Introduction:
Acute kidney injury (AKI) is a critical complication in severe COVID-19 cases, affecting up to 40% of patients. A recent study conducted in Colombia analyzed the clinical and laboratory characteristics of COVID-19 patients who developed AKI and received renal replacement therapy using the GENIUS® 90 technology.
Visit https://www.clinnephrologyjournal.com/jcn for more groundbreaking research in nephrology.
Key Findings:
- Patient Demographics: 78.9% were male, with an average age of 64 years.
- Common Comorbidities: Hypertension (65.3%), diabetes mellitus (38.9%), and obesity (26.3%).
- Inflammatory Markers: Elevated levels of CRP (20.3 mg/dl), d-dimer (931 mcg/L), and ferritin (1174 ng/ml).
- Renal Replacement Therapy: 63.5% received sustained low-efficiency dialysis (SLED), while 36.5% underwent conventional hemodialysis.
- Mortality Rate: 36.9% overall, with a lower mortality in CKD patients (18.7%) compared to non-CKD patients (40.1%).
Significance of GENIUS® 90 Technology
The study highlights the potential benefits of intermittent and prolonged renal replacement therapy in managing AKI in critically ill COVID-19 patients. GENIUS® 90 offers a safe, effective, and cost-efficient alternative to traditional continuous therapies.
Broader Implications in Nephrology
The American Society of Nephrology (ASN) emphasizes the growing burden of AKI in hospitalized COVID-19 patients and the need for innovative dialysis solutions to improve outcomes.
Read the full study at https://doi.org/10.29328/journal.jcn.1001059.
Call to Action:
Explore more studies at https://www.clinnephrologyjournal.org/jcn and share your thoughts in the comments below!
Disclaimer: This content is generated using AI assistance and should be reviewed for accuracy and compliance before considering this article and its contents as a reference.Any mishaps or grievances raised due to the reusing of this material will not be handled by the author of this article.
Heighten Science Publications Inc. 
Leave a comment